Conference Coverage
Conference Coverage
First-line obinutuzumab monotherapy in CLL linked to good response, reduced toxicity
NEW YORK – Obinutuzumab monotherapy effective for the first-line treatment of chronic lymphocytic leukemia.
Conference Coverage
Copanlisib makes inroads against relapsed/refractory follicular lymphoma
LUGANO, SWITZERLAND – New PI3K inhibitor promises better safety and efficacy for ongoing treatment.
Conference Coverage
Combo demonstrates activity in CLL/SLL and FL
LUGANO, SWITZERLAND—Results of a phase 1 study suggest a 2-drug combination may be safe and effective in patients with chronic lymphocytic...
Conference Coverage
Tazemetostat active against follicular lymphoma with EZH2 mutation
LUGANO, SWITZERLAND - Patients most likely to respond to tazemetostat were those with activating mutations in EZH2 and MYD88.
Conference Coverage
NF-kB inhibitor IT-901 shows promise in Richter syndrome
In vitro analyses of primary leukemic cells and in vivo analyses in patient-derived xenograft models indicate NF-kB inhibition should be...
Conference Coverage
Telomere length predicts FCR response in CLL patients
NEW YORK – Telomere length reliably predicts response to fludarabine-cyclophosphamide-rituximab (FCR) treatment in patients with chronic...
Conference Coverage
CAR T-cell therapy shows early promise in DLBCL
LUGANO, SWITZERLAND—The chimeric antigen receptor (CAR) T-cell therapy JCAR017 can produce “potent and durable” responses in patients with...
Conference Coverage
Ibrutinib/buparlisib looks good for relapsed mantle cell lymphoma
LUGANO, SWITZERLAND – The overall response rate among patients with mantle cell lymphoma in a phase I/IB dose escalation study was 100%,...
Conference Coverage
Pembrolizumab + rituximab boost response rates in relapsed follicular lymphoma
LUGANO, SWITZERLAND – The overall response rate with the combination was 65%, including 50% complete responses, in 20 patients with relapsed...
Conference Coverage
CARs race for supremacy against aggressive non-Hodgkin lymphoma
MADRID - Two chimeric antigen receptor T cell (CAR-T) constructs are showing promising activity against treatment-refractory, aggressive forms of...